Fig. 4

Shisa3 interacts with FGFR to impact EGFR-TKI sensitivity. a. Cell lysates from PC9/ER cells transfected with Flag-Shisa3 were immunoprecipitated with Flag or IgG and blotted with FGFR1, FGFR3, and Flag antibodies. b. Western blot analysis in cellular extracts of indicated cells. c. Representative images (× 200 magnification) of FGFR1 staining by immunohistochemical analysis in tumor tissues. Scale bars, 50 μm. d. Histogram of the negative relationship between shisa3 and FGFR1 expression in lung adenocarcinoma tissues with EGFR mutations (n = 102). e, f. Kaplan-Meier analysis of the DFS (e) and OS (f) of lung adenocarcinoma patients (n = 102) in connection with FGFR1 expression. G. PC9/ER-control and PC9/ER-shisa3 cells were incubated with the following agents: gefitinib (0.5 μM), osimertinib (0.1 μM), BGJ398 (1 μM), or a combination of gefitinib/osimertinib and BGJ398. g: n.s. p > 0.05; *p < 0.05; **p < 0.001; ***p < 0.0001